Home | Risk calculator | Publications | Collaborators | Statistical Methods

HIV Paediatric Prognostic Markers Collaborative Study. Discordance between CD4 cell count and CD4 percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 2010; 24:1213-17. Reference

HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving to antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362:1605-11. Reference

HIV Paediatric Prognostic Markers Collaborative Study. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 2005; 366:1868-74. Reference

HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 count for disease progression in untreated HIV-1-infected children. AIDS 2006, 20: 1289-1294. Reference

Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K, for the HIV Paediatric Prognostic Markers Collaborative Study and the Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008, 197:398-404. Reference